Home › Compare › DAHSF vs ABBV
DAHSF yields 8.97% · ABBV yields 3.06%● Live data
📍 DAHSF pulled ahead of the other in Year 1
Combined, DAHSF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of DAHSF + ABBV for your $10,000?
Dah Sing Financial Holdings Limited, an investment holding company, provides banking, insurance, financial, and other related services in the People's Republic of China. The company operates through Personal Banking, Corporate Banking, Treasury and Global Markets, Overseas Banking, and Insurance Business segments. The Personal Banking segment accepts various deposits from individual customers; and provides residential mortgage loans, personal loans, overdrafts, vehicle financing, and credit card services, as well as insurance sales and investment services. The Corporate Banking segment accepts various deposits; and offers loans and working capital financing to commercial, industrial, and institutional customers, as well as trade financing services. The Treasury and Global Markets segment provides foreign exchange services; cash management services for deposit taking and lending; and interest rate risk management services. It also manages investment in securities. The Overseas Banking segment offers personal and corporate banking products and services. The Insurance Business segment is involved in the insurance and pension fund management business. The company also provides insurance agency, nominee, and securities dealing services; and invest in properties. The company was formerly known as Fivetech Investments Limited and changed its name to Dah Sing Financial Holdings Limited in July 1987. Dah Sing Financial Holdings Limited was founded in 1947 and is based in Wan Chai, Hong Kong.
Full DAHSF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.